Apstatin (TFA)

Apstatin TFA is a potent aminopeptidase P (APP) inhibitor with Ki values of 2.6, 0.64 µM for rat and human APP, respectively. Apstatin TFA shows cardioprotection[1][2].

Product Specifications

UNSPSC

12352211

Target

Aminopeptidase

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Purity

99.43

Smiles

C[C@@H](C(N)=O)NC([C@H]1N(C([C@H]2N(C([C@@H](O)[C@H](N)CC3=CC=CC=C3)=O)CCC2)=O)CCC1)=O.O=C(O)C(F)(F)F

Molecular Formula

C25H34F3N5O7

Molecular Weight

573.56

References & Citations

[1]Wolfrum S, et al. Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway. Br J Pharmacol. 2001 Sep;134 (2) :370-4. |[2]Maggiora LL, et al. Apstatin analogue inhibitors of aminopeptidase P, a bradykinin-degrading enzyme. J Med Chem. 1999 Jul 1;42 (13) :2394-402.